Blood pressure drug beats rival meds in PhIII; MiddleBrook files Chap. 11; AZ to pay Targacept $11M for expanded pact;

 @FierceBiotech: Dendreon: Provenge to cost $93K for full course of treatment. Report | Follow @FierceBiotech 

 @JohnCFierce: The Provenge approval creates an illusion of fast progress with cancer vaccines; developers will soon be back to the same old snail's pace. | Follow @JohnCFierce

> Takeda's experimental azilsartan medoxomil, an angiotensin receptor blocker, outperformed two rival blood pressure meds in a late-stage study. Analysts project that the therapy could earn more than $700 million a year if approved. Story

> Westlake, TX-based MiddleBrook Pharmaceuticals filed for Chapter 11 bankruptcy protection. The company markets anti-infective treatments. Release

> AstraZeneca is making an $11 million payment to Targacept after amending their 2005 pact for TC-5619. Release

> BioSante Pharmaceuticals says it has reinitiated development of its GVAX Prostate Cancer Vaccine. Release

> Forbes' Matthew Herper has begun a new monthly feature looking over the big winners and loser in the biotech game. Delcath Systems and Genvec get the once-over for April. Story

> Interleukin Genetics CEO Lewis Bender took a 61 percent cut in pay for 2009. Story

> San Diego-based Althea Technologies has acquired the assets and IP portfolio of Altus Pharmaceuticals. Release

> Celator Pharmaceuticals announced positive results from its Phase II study of CPX-351 Liposome Injection versus conventional cytarabine and daunorubicin in AML patients 60-75 years of age. Release

> Genesis Research is shutting down its New Zeland ops after running out of cash. Report

And Finally... Whether different odors can be quickly distinguished depends on certain synapses in the brain that inhibit nerve stimulation. Release

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.